Alpha Cognition Inc. launched its flagship Alzheimer’s drug, ZUNVEYL, in early 2025 following FDA approval in mid-2024. Despite commercialization efforts targeting the long-term care market, the company reported a steep revenue drop in FY2025 alongside widening operating losses and significant cash burn. The firm remains heavily reliant on a single product and must balance aggressive market access strategies against reimbursement hurdles and manufacturing risks. Its longer-term growth hinges on pipeline advancement and commercial scaling amid intense competition from established therapies and emerging disease-modifying drugs.